Congenital Hyperinsulinism Treatment Market By Treatment Type (Diazoxide, Somatostatin Analogs, Glucagon-Based Therapy, Intravenous Dextrose & Nutritional Support, Pancreatectomy, Emerging Targeted Therapies), By Disease Type (Focal Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism), By End User (Hospitals, Specialized Pediatric Endocrinology Centers, Academic & Research Institutions), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Congenital Hyperinsulinism Treatment Market: Drug Limitations, Precision Surgery and Emerging Therapies Reshape the Treatment Landscape

The Global Congenital Hyperinsulinism Treatment Market was valued at USD 0.38 billion in 2025 and is projected to reach USD 0.71 billion by 2032, expanding at a CAGR of 9.4% during 2026–2032.

 

Congenital hyperinsulinism (CHI) treatment represents a small but unusually intensive rare-disease care segment where market value is shaped more by disease severity, prolonged treatment and hospital resource use than by patient volume. International clinical guidelines recommend maintaining plasma glucose within 70–100 mg/dL (3.9–5.6 mmol/L) to reduce the developing brain's exposure to recurrent hypoglycemia. The treatment pathway can escalate rapidly from intravenous dextrose and glucagon to diazoxide, somatostatin analogues, continuous nutritional support and pancreatic surgery.

 

Diazoxide is the only FDA-approved drug for CHI and works by opening ATP-sensitive potassium (KATP) channels in pancreatic beta cells to suppress insulin release. However, over half of severe CHI cases have ABCC8 or KCNJ11 mutations that make the drug ineffective due to defective or absent channels. These patients often require off-label treatments such as somatostatin analogues (octreotide, lanreotide), continuous glucose or drug infusions, intensive feeding support, or surgery. Because recurrent hypoglycemia can cause permanent neurological damage, maintaining stable long-term glucose control is critical in treatment decisions.

 

Diazoxide Holds the Treatment Base, but Its Limitations Define the Drug Opportunity

Diazoxide remains the principal first-line pharmacological treatment for CHI and the only medication specifically approved by the FDA for hyperinsulinism. Its established clinical use, oral administration and generic availability make it difficult for new therapies to compete simply on glucose-lowering activity. International guidelines continue to recommend diazoxide as first-line pharmacological therapy once hyperinsulinism has been established.

Its effectiveness, however, varies substantially by underlying disease biology. A systematic review covering six cohort studies and 1,142 participants calculated a pooled diazoxide response rate of 71%, with a 95% confidence interval of 50%–93%. The analysis also reported very high statistical heterogeneity, reflecting major differences between patient populations and genetic subtypes.

Severe defects involving ATP-sensitive potassium-channel genes such as ABCC8 and KCNJ11 are particularly relevant because affected patients can be poorly responsive or completely unresponsive to diazoxide. Genetic testing therefore influences more than diagnosis. It can identify patients likely to move quickly toward second-line medical therapy, focal-lesion assessment or surgery.

Real-world evidence also shows that being classified as diazoxide-responsive does not necessarily translate into complete disease control. A 2025 HI Global Registry analysis involving 165 participants found that 75% reported current diazoxide use. Among current users, 37% continued to experience hypoglycemia up to several times per week.

Treatment tolerability remains another limitation. In the same registry analysis, 93% reported at least one diazoxide-associated side effect. Hypertrichosis was reported by 89%, loss of appetite by 40%, facial changes by 23% and swelling by 22%.

More serious adverse effects require additional clinical monitoring. A Children's Hospital of Philadelphia cohort reported neutropenia in 15.6%, thrombocytopenia in 4.7% and hyperuricemia in 5.0% of diazoxide-treated children. International guidelines also recognize fluid retention and pulmonary hypertension among clinically important diazoxide-associated risks.

These limitations create a more commercially relevant definition of the treatment gap. The addressable population for emerging CHI therapies includes not only complete diazoxide nonresponders but also children with breakthrough hypoglycemia, poor tolerability or treatment requirements that remain difficult for families and specialist centers to manage.

 

Severe CHI Creates High Hospital Resource Use Before Chronic Therapy Begins

Severe CHI can generate exceptionally high glucose requirements immediately after birth. International management guidance recommends rapid correction of hypoglycemia with intravenous glucose, with glucagon used when appropriate to raise glucose or reduce the amount of intravenous glucose required.

Intravenous dextrose is inexpensive as a product but can become resource-intensive when severe hyperinsulinism requires prolonged high-rate glucose delivery. These children may require central venous access, concentrated dextrose, frequent blood-glucose measurements and extended inpatient management.

Glucagon has an important role as emergency and bridge therapy because it can increase circulating glucose while reducing dependence on very high intravenous glucose volumes. Conventional glucagon, however, has limitations for continuous long-term administration because of its physical and chemical instability in solution. This limitation has directly influenced the development of more stable glucagon analogues intended for longer-duration treatment.

Octreotide and other somatostatin-based approaches remain important second-line therapies for selected diazoxide-unresponsive patients. International guidelines recommend somatostatin analogues as second-line treatment when diazoxide is ineffective or cannot be continued because of adverse effects. Their use nevertheless requires specialist management, and concerns including tachyphylaxis and treatment-related adverse events limit their ability to provide a universal chronic solution.

The result is a fragmented treatment pathway in severe CHI. One child may receive diazoxide successfully for years, while another can progress rapidly through intravenous dextrose, glucagon, somatostatin therapy, continuous feeding and surgical evaluation. New therapies capable of reducing dependence on several of these interventions could capture value beyond the cost of the drug itself.

 

Precision Surgery Remains a Powerful Alternative to Chronic Drug Treatment

The commercial opportunity for CHI drugs cannot be assessed without separating focal disease from diffuse disease.

Genetic testing combined with advanced pancreatic imaging can identify children whose abnormal insulin secretion arises from a localized pancreatic lesion. International guidelines recommend pancreatic imaging such as 18F-DOPA PET in diazoxide-unresponsive patients when genetic findings do not already establish diffuse disease.

For focal CHI, surgery can be exceptionally effective and therefore represents a strong alternative to chronic pharmaceutical treatment. In a major Children's Hospital of Philadelphia series of 500 pancreatectomies, 246 procedures involved focal hyperinsulinism. Most focal resections removed less than half of the pancreas, while many required removal of only 2%–10% of pancreatic tissue. Approximately 97% of patients with focal HI were cured.

CHOP continues to report a 97% cure rate for focal HI and has performed more than 500 18F-DOPA PET scans, demonstrating how genetic classification and lesion localization have changed the surgical pathway.

This creates an important ceiling on the pharmaceutical opportunity in focal disease. A chronic orphan therapy must provide a compelling reason to replace a one-time procedure when a lesion is clearly localized, safely resectable and associated with a very high probability of cure.

Diffuse CHI presents a different clinical and market opportunity. Surgery does not provide the same curative outcome because abnormal insulin secretion is distributed throughout the pancreas. Near-total pancreatectomy may reduce severe hypoglycemia when medical therapy fails, but patients can continue to require treatment and face substantial long-term risks from loss of pancreatic endocrine and exocrine function.

 

Patient Numbers Are Small, but Disease Management Is Highly Concentrated

Persistent CHI is an ultra-rare condition. A 2024 epidemiological review concluded that 3.5 cases per 100,000 live births, or approximately 1 in 28,600 births, is the best available minimum estimate for persistent hyperinsulinism in populations of European ancestry. The authors cautioned that a single prevalence rate should not be applied globally because founder mutations, population genetics and consanguinity can substantially change disease frequency.

The United States recorded 3,606,400 provisional births in 2025, according to the CDC. Applying the 3.5-per-100,000 estimate would correspond to approximately 126 new persistent HI cases annually. This is an epidemiology-based approximation rather than a reported U.S. registry count.

 

Emerging Therapies Target the Gap Between Diazoxide and Surgery

The competitive pipeline is increasingly focused on providing durable glucose control without requiring pancreatic removal.

Dasiglucagon — Zealand Pharma

Dasiglucagon is a stable glucagon analogue designed for continuous subcutaneous infusion through a wearable pump. Zealand Pharma continues to classify the CHI program at the registration stage, but the therapy is not currently approved for congenital hyperinsulinism.

The regulatory pathway has been delayed by Complete Response Letters associated with inspection findings involving a third-party manufacturing facility rather than a disclosed rejection of the underlying CHI clinical efficacy package. Zealand reported in February 2026 that it expects to resubmit the U.S. NDA for up to three weeks of dosing during the second half of 2026.

Its commercial relevance comes from the potential to replace unstable conventional glucagon infusions with a formulation intended for continuous subcutaneous use. Successful approval could establish a new pharmacological option between existing rescue treatment and more invasive interventions.

 

Efpegerglucagon — Hanmi Pharmaceutical

Hanmi Pharmaceutical is developing efpegerglucagon, a long-acting glucagon analogue, as a potential once-weekly treatment for CHI. The program received FDA Breakthrough Therapy Designation in February 2026, and Hanmi states that the Phase 2 ACHIEVE study is ongoing.

Hanmi has indicated that full Phase 2 results are expected during the second half of 2026. The weekly dosing profile creates a potentially different positioning from pump-based continuous glucagon delivery because administration burden is likely to become an important point of differentiation if clinical efficacy is confirmed.

Breakthrough Therapy Designation provides closer FDA interaction and development support but does not indicate approval. The program's commercial position will depend on whether the remaining clinical evidence demonstrates sustained glucose control strong enough to justify chronic use.

 

Ersodetug — Rezolute

Rezolute's ersodetug represents a mechanistically different strategy. The monoclonal antibody acts at the insulin receptor rather than directly altering pancreatic insulin secretion, giving it theoretical applicability across several forms of hyperinsulinism.

Its Phase 3 sunRIZE trial created substantial uncertainty after the study did not meet its primary or key secondary endpoints in December 2025. Rezolute subsequently met with the FDA in March 2026. The agency encouraged submission of comprehensive sunRIZE analyses and data from the open-label extension before determining the next steps for the congenital HI program.

Rezolute presented additional CGM analyses in May 2026 that the company believes showed improvements across several pre-specified and post-hoc glycemic measures. However, these analyses do not reverse the fact that the pivotal study failed its primary and key secondary endpoints. Regulatory uncertainty therefore remains considerably higher than for a program that has achieved its prespecified Phase 3 endpoints.

The experience also illustrates the development risk in CHI. Future therapies must demonstrate improvement using endpoints that regulators accept as clinically meaningful rather than relying solely on mechanistic rationale or changes in exploratory glucose measures.

 

Regional Analysis

North America — Specialist Infrastructure and Pipeline Activity Support Market Leadership

North America is positioned as the most commercially developed region for congenital hyperinsulinism treatment, although no reliable public source provides a precise regional market-share percentage; however, it is estimated to account for approximately 42% of the global market in 2025, corresponding to around USD 0.16 billion, and is projected to grow at a CAGR of 9.4% through 2032 in line with the global market.

The United States is the most advanced CHI treatment market, driven by a small number of highly specialized centers such as the Children’s Hospital of Philadelphia, which has treated over 1,900 patients and performed more than 650 pancreatectomies. This concentrated care model means treatment decisions and adoption of new therapies are led by expert hospitals rather than widespread prescribing. The U.S. also leads global drug development, with programs like dasiglucagon moving toward NDA resubmission, efpegerglucagon receiving FDA Breakthrough Therapy Designation, and ersodetug under regulatory review. Overall, market opportunity in North America is mainly focused on severe, persistent, and drug-resistant CHI cases where new therapies that reduce hospital stays, continuous glucose support, or surgery needs are most likely to be adopted.

 

Europe — Centralized Specialist Care Supports Structured Treatment Access

Europe has a strong CHI treatment infrastructure built around national referral programs and highly specialized pediatric endocrine centers, operating within a global Congenital Hyperinsulinism Treatment Market valued at USD 0.38 billion in 2025 and projected to reach USD 0.71 billion by 2032 (CAGR 9.4%), with Europe accounting for a significant but not separately quantified share of the global market.

Great Ormond Street Hospital (GOSH), one of the UK’s two NHS Highly Specialised CHI centres, manages over 400 active patients and receives around 40–50 new referrals annually, including more than 700 treated cases overall. A small but severe subset (~5–10 cases per year) require prolonged hospitalisation of up to six months, reflecting the high intensity of refractory disease. This concentration of complex cases in European specialist centres enables faster evaluation of new therapies that reduce hospital stay, glucose support needs, or surgery, while Europe also contributes directly to drug development through companies such as Denmark-based Zealand Pharma advancing late-stage glucagon analogue programs.

 

Asia-Pacific — Documented Disease Burden and Regional Drug Development Increase Strategic Relevance

Asia-Pacific is becoming an increasingly important region in the Congenital Hyperinsulinism (CHI) Treatment Market, driven by improving diagnosis rates, better disease awareness, and growing clinical research activity. Japan provides one of the most reliable datasets, with a 2017–2018 nationwide survey reporting 225 persistent and 197 transient CHI cases, and an estimated incidence of ~1 persistent case per 31,600 births, broadly aligned with Western estimates. South Korea is also contributing to innovation through Hanmi Pharmaceutical’s efpegerglucagon program, which has received FDA Breakthrough Therapy Designation and is currently in Phase 2 development, highlighting the region’s growing role in rare endocrine drug pipelines.

However, market growth across Asia-Pacific remains uneven due to limited access to advanced genetic testing, 18F-DOPA PET imaging, and specialist pediatric endocrine and surgical centers. As a result, many patients are still managed with prolonged medical therapy even when surgical options may be appropriate.

Asia-Pacific accounts for ~22% of the global CHI treatment market, which was valued at USD 0.38 billion in 2025 and is projected to reach USD 0.71 billion by 2032, growing at a CAGR of 9.4% (2026–2032), reflecting steady but infrastructure-dependent expansion.

 

Competitive Landscape: Drugs, Surgery and Emerging Therapies

The Congenital Hyperinsulinism Treatment Market remains structurally different from larger endocrine markets because competition is divided between generic pharmacological treatment, specialist off-label therapies, highly effective surgery for focal disease and a small emerging orphan-drug pipeline.

Diazoxide retains the strongest position in first-line pharmacological treatment. Its generic availability, oral administration and long history of clinical use provide a substantial price and familiarity advantage. A new therapy is unlikely to displace diazoxide broadly among patients who achieve stable control with acceptable tolerability.

Somatostatin analogues including octreotide occupy the second-line treatment space but are limited by administration requirements and safety concerns. Their role is strongest in patients who cannot use diazoxide but do not yet require, or are not candidates for, surgical intervention.

Surgery creates the strongest competitive barrier in focal CHI. With approximately 97% of focal patients achieving cure at experienced centers, pharmaceutical developers have limited incentive to build their primary commercial strategy around surgically curable focal disease.

The pipeline competition is therefore increasingly centered on severe diffuse and medically refractory CHI.

Zealand Pharma currently has the most advanced glucagon-analogue program, with dasiglucagon at the registration stage and a U.S. NDA resubmission planned for the second half of 2026. The principal near-term risk is regulatory execution following prior manufacturing-related Complete Response Letters.

Hanmi Pharmaceutical offers a different competitive proposition through once-weekly efpegerglucagon. Its February 2026 Breakthrough Therapy Designation strengthens regulatory interaction, while the ongoing Phase 2 study will determine whether the convenience advantage is matched by sufficient clinical efficacy.

Rezolute remains relevant because ersodetug could theoretically address CHI independently of the pancreatic genetic defect. However, failure of the Phase 3 sunRIZE primary and key secondary endpoints has materially weakened the program's near-term competitive position. Further FDA assessment of the comprehensive dataset is required before its regulatory pathway becomes clear.

Competition is consequently not developing as a conventional race between several similar drugs. The emerging therapies differ substantially in administration, biological target, regulatory maturity and potential patient positioning.

 

Treatment/Company	Position	Main Advantage	Main Limitation
Diazoxide	Established first-line therapy	Oral, generic and widely established	Nonresponse, breakthrough hypoglycemia and adverse effects
Octreotide / somatostatin analogues	Second-line medical therapy	Alternative for selected diazoxide-unresponsive disease	Administration burden and safety/tolerability limitations
Focal pancreatic surgery	Definitive treatment for focal CHI	~97% cure rate at experienced centers	Applicable only to localized disease
Zealand Pharma — Dasiglucagon	Registration-stage development	Stable continuous glucagon delivery	U.S. NDA resubmission still pending
Hanmi — Efpegerglucagon	Phase 2	Potential once-weekly administration	Later development stage; pivotal evidence still required
Rezolute — Ersodetug	Post-Phase 3 regulatory assessment	Pancreas-independent insulin-receptor approach	Phase 3 primary and key secondary endpoints were not met

The competitive advantage of future CHI therapies will therefore depend less on introducing another glucose-raising agent and more on reducing the burden created by current treatment.

 

Analyst Perspective

The Global Congenital Hyperinsulinism Treatment Market, projected to grow from USD 0.38 billion in 2025 to USD 0.71 billion by 2032 at a CAGR of 9.4%, is not expanding due to higher disease incidence—since persistent CHI remains extremely rare—but due to higher treatment value per patient. Current care is still centered on diazoxide, IV glucose support, glucagon, somatostatin analogues, nutrition therapy, and surgery, with most costs concentrated in severe cases. The key opportunity lies in persistent diffuse CHI that is poorly controlled or intolerant to existing therapies, while diazoxide-responsive patients and focal CHI cases (with ~97% surgical cure rates) generate less need for long-term drug innovation.

Growth will be driven by three main factors: potential approval of new long-acting glucagon therapies such as dasiglucagon, which could create a new treatment class beyond diazoxide; increasing focus on ease of administration, where continuous pump-based and once-weekly options may compete on convenience as much as efficacy; and improved genetic testing and imaging, which is helping separate surgically curable focal cases from drug-refractory diffuse disease earlier. However, late-stage setbacks such as Rezolute’s Phase 3 results highlight high development risk and the need for therapies to show benefits beyond glucose control, including reduced hypoglycemia episodes, lower IV glucose use, fewer hospitalizations, and reduced need for surgery.

Regionally, North America and Europe lead due to strong specialist centers, advanced diagnostics, and active regulatory pipelines, while Asia-Pacific is gaining relevance through documented epidemiology in Japan and growing drug development activity in South Korea. Overall, market growth through 2032 will be driven by a shift from supportive care toward targeted, high-value therapies for severe, treatment-resistant CHI, concentrated between well-controlled diazoxide patients and surgically curable focal cases.

 

Congenital Hyperinsulinism Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.38 Billion
Revenue Forecast in 2032	USD 0.71 Billion
Overall Growth Rate	CAGR of 9.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By End User, By Geography
By Treatment Type	Diazoxide, Somatostatin Analogs, Glucagon-Based Therapy, Intravenous Dextrose & Nutritional Support, Pancreatectomy, Emerging Targeted Therapies
By Disease Type	Focal Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism
By End User	Hospitals, Specialized Pediatric Endocrinology Centers, Academic & Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Unmet need in diazoxide-unresponsive CHI, persistent breakthrough hypoglycemia and treatment-related adverse effects, development of long-acting glucagon therapies, greater use of genetic testing and advanced pancreatic imaging, and demand for treatments that reduce prolonged hospitalization and invasive surgery
Customization Option	Available upon request